Vaccines developed against the pandemic are on the way to create a new and huge market around the world. Market research firm Brandessence estimated that the size of the vaccine market will reach $ 75.75 billion by the end of this year. Fortune Business Insights predicted a market size of over $ 93 billion in 2026. The Guardian newspaper also wrote in its comprehensive analysis that the vaccine production of Pfizer-BioNTech, the leader of the market, could reach 2 billion doses and its revenues could reach 30 billion dollars. Return to normal life, promising vaccines, drug companies and is an important export for countries like Turkey or in the position of the recipient country has become import item. Many different vaccines, whose prices vary from country to country and from agreement to agreement, are earning billions of dollars to manufacturing companies. Brandessence Market Research says the coronavirus vaccine market, which was only $ 370 million last year, will see $ 75.75 billion by the end of this year with the pandemic. Fortune Business Insights predicts that the vaccine market will exceed $ 93 billion by 2026, but sales this year alone indicates that the market will rapidly run to $ 100 billion. In the analysis compiled from company statements and publicly disclosed deals, The Guardian newspaper describes how much the company will earn and how its shares have changed in the past year if they are listed:
Pfizer- BioNTech: The Mrna vaccine, which needs to be transported in ultra-low temperatures like minus 70 degrees (-25 to -15 degrees last week, but only two weeks said), the Mrna vaccine will provide companies 15 to 30 billion dollars in revenue in 2021. Barclays analysts said the company's two doses were $ 21.5 from the $ 30 to $ 40 vaccine this year; It predicts sales of $ 8.6 billion in 2022 and $ 1.95 billion in 2023. Pfizer shares rose 1.8 percent in the last 12 months, while BioNTech, the main owner of the technology for which the vaccine was developed, rose 156 percent. Guardian adds that Uğur Şahin and Özlem Türeci became billionaires with the Pfizer deal.
Moderna: Mrna vaccine, which can be transported at -20 degrees, is expected to bring US-based company sales of $ 18.4 billion in 2021. This year, it was $ 19.6 billion, according to Barclays analysts; There will be sales of $ 12.2 billion next year and $ 11.4 billion in 2023. The company's shares have risen 372 percent in the last 12 months.
Johnson & Johnson: The vaccine, which is the first single-dose vaccine and developed by the company's Belgian unit, is expected to sell for $ 10 billion in 2021. The company's goal is to produce 1 billion doses this year from the vaccine, which costs $ 10 per dose. There has been an increase of 7.7 percent in the company's share in the last year.
AstraZeneca- Oxford: Due to the much cheaper AstraZeneca vaccine, one of the leading COVID-19 vaccines ($ 4 to $ 10 per dose), the projected 2021 sales figure is $ 2 to $ 3 billion. However, the production target of three billion doses in 2021 may raise this figure. The UK (100 million doses), the EU (400 million doses), the USA (300 million doses) and Japan (120 million doses) are big order countries. The company's shares are down 8.6 percent from last year, especially with some variants reducing their effectiveness. Sinovac: Turkey, Indonesia, Brazil, Chile, Singapore, Malaysia and the Philippines are engaged in an agreement with the Chinese company coronovac vaccine is still imperative to perform the billions of dollars in sales figures full of uncertainty. The vaccine, which has two doses of $ 60 in China and is expected to produce 1 billion doses this year, is expected to be $ 27.20 for two doses in Indonesia.
Gamaleya Institute: The company, which developed the SputnikV vaccine and received the support of the Russian state fund, already has agreements with 15 manufacturers in 10 countries to produce a total of 1.4 billion doses. The vaccine, which is offered free of charge in Russia, will offer manufacturers the vaccine for two doses at a price of $ 20 or less. In other words, the SputnikV vaccine will bring the company at least $ 15-20 billion in sales.
Novavax: The vaccine of the US company, whose shares have increased by 1.128 percent in the last 12 months and is waiting for approval in the UK and USA in the first half of the year, was developed from the spike protein of the Sars-Cov-2 virus. The company, which pre-sold a total of 300 million doses to the UK, USA, Canada and Australia without the approval of the authority, will sell the dose to Africa for 3 dollars. The company, which has a production target of 2 billion doses, is expected to generate billions of dollars in revenue by the middle of 2021, thanks to the production agreement with the Indian Serum Institute.
CureVac: The German CureVac, whose shares have increased by 45.5 percent in the last year, is waiting to receive approval for its vaccine in the EU as of June. The final stage clinical trial results of the CVnCov vaccine, which can be transported at refrigerator temperature, will be announced in April, but the EU has already ordered 225 million doses. The company aims to develop new generation vaccines against all new variants with British GlaxoSmithKline, which also owns 10 percent. While only 300 million doses are foreseen to be produced this year, there is no forecast for sales as the price is not yet determined.
Calls to 'not buy' Russian and Chinese vaccines in Europe
The COVID-19 vaccines, which are seen as 'Western' vaccines, Chinese vaccines and Russian vaccines by politicians and press organizations due to the vaccine nationalism and the inhomogeneity of the scientific processes of the countries, have recently created controversy within the European Union. Clement Beaune, the Minister of EU Affairs of France, told RTL Radio, urging EU countries not to take Russian and Chinese vaccines in Europe without approval in order not to risk the unity of the bloc and public health.
The SputnikV vaccine is currently approved in Hungary, in Slovakia and Czechia under evaluation. Hungary has already started vaccinating with both the Sinopharm vaccine and SputnikV. The drug authority EMA announced last week that it started its SputnikV review, but even if the EMA approves, the European Commission may choose not to receive Sputnik or any Chinese vaccine in its joint purchases. On the other hand, the Johnon & Johnson vaccine, which was developed much later than SputnikV, could get European approval on March 11.
